Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/17/2017 01/18/2017 01/19/2017 01/20/2017 01/23/2017 Date
33.25(c) 32.5(c) 32.5(c) 32.375(c) 31.5(c) Last
178 381 82 885 91 913 29 496 109 378 Volume
+0.38% -2.26% 0.00% -0.38% -2.70% Change
More quotes
Financials ( GBP)
Sales 2017 15,2 M
EBIT 2017 -37,8 M
Net income 2017 -32,2 M
Finance 2017 8,17 M
Yield 2017 -
Sales 2018 42,9 M
EBIT 2018 -19,5 M
Net income 2018 -11,6 M
Finance 2018 6,71 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 10,6x
EV / Sales2018 3,82x
Capitalization 170 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
2016 VERNALIS : Says US FDA Accepts CCP-08 Cough Drug For Full Review
2016 VERNALIS : FDA accepts CCP-08 NDA for full review
2016 VERNALIS PLC : FDA accepts CCP-08 NDA for full review
2016 VERNALIS PLC : AGM Statement
2016 VERNALIS : Takes Steps To Drive Demand For Tuzistra, Progress Pipeline
2016 VERNALIS : Notice of Annual Report and AGM
2016 VERNALIS : Begins Promotion Of MOXATAG® Amoxicillin Extended-Release Tablets To ..
2016 VERNALIS : *panmure cuts vernalis plc price target to 65 (76) pence - 'buy'
2016 VERNALIS : Makes "Significant Progress" In Year On Tuzistra's US Launch
2016 VERNALIS : Results Announcement for the 12 months ended 30 June 2016
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2016Graeme Davies: News & Tips: Telford Homes, Vernalis, Wincanton & mor.. 
2016Vernalis plc's  house stock rating reiterated at Shore Capital.
1
2016Vernalis plc's  buy rating reiterated at Canaccord Genuity. GBX 88 PT.  
2016Vernalis : FDA accepts CCP-08 NDA for full review  
2016Vernalis plc's buy rating reiterated at Panmure Gordon. GBX 65 PT.  
More tweets
Qtime:21
News from SeekingAlpha
2016 Vernalis reports FY16 results
2016 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,80  GBP
Spread / Average Target 147%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-7.35%211
INCYTE CORPORATION17.10%22 083
QUINTILES IMS HOLDINGS..-0.26%18 734
CELLTRION, INC.--.--%10 483
LONZA GROUP AG4.03%9 679
ALKERMES PLC0.29%8 507
More Results